Soleno Therapeutics, Inc.
SLNO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 2.49 | 0.75 | 0.29 |
| FCF Yield | 1.21% | -0.30% | -0.99% | -1.22% |
| EV / EBITDA | 120.45 | -1,486.13 | -78.05 | -39.20 |
| Quality | ||||
| ROIC | 3.90% | -2.09% | -15.10% | -18.90% |
| Gross Margin | 98.27% | 97.87% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.68 | 2.68 | 0.75 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 4,620,897.27% | 3,196,282.63% | -100.00% | -100.00% |
| Free Cash Flow Growth | 445.81% | 61.48% | -36.49% | -58.76% |
| Safety | ||||
| Net Debt / EBITDA | -8.74 | 8.38 | 0.68 | 0.71 |
| Interest Coverage | 15.90 | -4.74 | -33.61 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.17 | 0.30 | 0.00 | 0.00 |
| Cash Conversion Cycle | -81.26 | -431.41 | 0.00 | 0.00 |